A szerzők az elhízás mozgásszervi vonatkozásait új megközelítésben, elsősorban annak metabolikus hatásait kiemelve ismertetik. Az elhízással és különösen a metabolikus szindrómával járó biokémiai változások megváltoztatják a csont, az ízületi struktúrák és az izomzat működését. Ezek alapján szemléletváltozás szükséges bizonyos kórképekben az eddig kialakult nézetekben. A gyulladásos reumatológiai betegségek lefolyásának súlyosságában és az alkalmazott kezelések megválasztásában is figyelembe kell venni az elhízással járó anyagcsere-változásokat. A társuló komorbiditások miatt a személyre szabott kezelés fontossága kiemelt jelentőségű. Orv Hetil. 2019; 160(44): 1727–1734.
WHO. Obesity and overweight. World Health Organization, Geneva, 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [accessed: June 9, 2019].
Health status and health behaviour 2016–2017. [Egészségi állapot és egészségmagatartás, 2016–2017]. Központi Statisztikai Hivatal, Statisztikai tükör, 2018. július 23. [Hungarian]
Anandacoomarasamy A, Caterson I, Sambrook P, et al. The impact of obesity on the musculoskeletal system. Int J Obes (Lond). 2008; 32: 211–222.
Pados Gy. Current treatment of obesity. [Az elhízás korszerű kezelése.] Orv Hetil. 2010; 151: 501–504. [Hungarian]
Halmy L, Fehér T, Steczek K, et al. High serum bile acid level in obesity: its decrease during and after total fasting. Acta Med Hung. 1986; 43: 55–58.
Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–1062.
International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. [A Nemzetközi Diabetes Társaság (IDF) ajánlása a metabolikus szindróma világszerte érvényes definíciójára.] Diabetol Hung. 2005; 13: 107–112. [Hungarian.]
Szigethy E, Széles G, Horváth A, et al. Epidemiology of the metabolic syndrome in Hungary. Public Health 2012; 126: 143–149.
Suba I, Halmos T, Kautzky L. The value of certain parameters in the diagnosis and detection of metabolic X syndrome. [Az egyes vizsgálati paraméterek értéke a metabolikus X-szindróma diagnózisában és felkutatásában.] Orv Hetil. 1997; 138: 2407–2411. [Hungarian]
Nishimura S, Manabe I, Nagai R. Adipose tissue inflammation in obesity and metabolic syndrome. Discov Med. 2009; 8: 55–60.
Collins KH, Herzog W, MacDonald GZ, et al. Obesity, metabolic syndrome, and musculoskeletal disease: common inflammatory pathways suggest a central role for loss of muscle integrity. Front Physiol. 2018; 9: 112.
Szekanecz Z. Osteoarthritis. In: Szekanecz Z, Nagy Gy. (eds.) Rheumatology. [Osteoarthritis. In: Szekanecz Z, Nagy Gy. (szerk.) Reumatológia.] Medicina Könyvkiadó, Budapest, 2019; pp. 451–470. [Hungarian]
Cicuttini FM, Baker JR, Spector TD. The association of obesity with osteoarthritis of the hand and knee in women: a twin study. J Rheumatol. 1996; 23: 1221–1226.
Dahaghin S, Bierma-Zeinstra SM, Koes BW, et al. Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study. Ann Rheum Dis. 2007; 66: 916–920.
Rejeski WJ, Focht BC, Messier SP, et al. Obese, older adults with knee osteoarthritis: weight loss, exercise, and quality of life. Health Psychol. 2002; 21: 419–426.
Miller GD, Nicklas BJ, Davis CC, et al. Is serum leptin related to physical function and is it modifiable through weight loss and exercise in older adults with knee osteoarthritis? Int J Obes Relat Metab Disord. 2004; 28: 1383–1390.
Miksi Á, Fazekas K, Flórián Á, et al. Relationship between metabolic syndrome and osteoporosis. [A metabolikus szindróma és az osteoporosis összefüggései.] Immunol Szle. 2018; 10: 4–9. [Hungarian]
Rosen CJ, Klibanski A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med. 2009; 122: 409–414.
Francisco V, Pino J, Campos-Cabaleiro V, et al. Obesity, fat mass and immune system: role for leptin. Front Physiol. 2018; 9: 640.
Abella V, Scotece M, Conde J, et al. Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat Rev Rheumatol. 2017; 13: 100–109.
Bredella MA, Lin E, Gerweck AV, et al. Determinants of bone microarchitecture and mechanical properties in obese men. J Clin Endocrinol Metab. 2012; 97: 4115–4122.
Carrelli A, Bucovsky M, Horst R, et al. Vitamin D storage in adipose tissue of obese and normal weight women. J Bone Miner Res. 2017; 32: 237–242.
Salamat MR, Salamat AH, Janghorbani M. Association between obesity and bone mineral density by gender and menopausal status. Endocrinol Metab (Seoul). 2016; 31: 547–558.
Janicka A, Wren TA, Sanchez MM, et al. Fat mass is not beneficial to bone in adolescents and young adults. J Clin Endocrinol Metab. 2007; 92: 143–147.
Chen YY, Fang WH, Wang CC, et al. Body fat has stronger associations with bone mass density than body mass index in metabolically healthy obesity. PLoS ONE 2018; 13: e0206812.
Sadeghi O, Saneei P, Nasiri M, et al. Abdominal obesity and risk of hip fracture: a systematic review and meta-analysis of prospective studies. Adv Nutr. 2017; 8: 728–738.
Liu CT, Broe KE, Zhou Y, et al. Visceral adipose tissue is associated with bone microarchitecture in the Framingham Osteoporosis Study. J Bone Miner Res. 2017; 32: 143–150.
Stenholm S, Harris TB, Rantanen T, et al. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care 2008; 11: 693–700.
Scott D, Johansson J, McMillan LB, et al. Associations of sarcopenia and its components with bone structure and incident falls in Swedish older adults. Calcif Tissue Int. 2019; 105: 26–36.
Finckh A, Turesson C. The impact of obesity on the development and progression of rheumatoid arthritis. Ann Rheum Dis. 2014; 73: 1911–1913.
Kerekes G, Nurmohamed MT, Gonzalez-Gay MA, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 2014; 10: 691–696.
Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE 2018; 13: e0195123.
Qin B, Yang M, Fu H, et al. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res Ther. 2015; 17: 86.
Feng J, Chen Q, Yu F, et al. Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies. Medicine (Baltimore) 2016; 95: e2859.
da Cunha VR, Brenol CV, Brenol JC, et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol. 2012; 41: 186–191.
Pedersen M, Jacobsen S, Klarlund M, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther. 2006; 8: R133.
Lu B, Hiraki LT, Sparks JA, et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis. 2014; 73: 1914–1922.
Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012; 71: 1267–1272.
Eder L, Abji F, Rosen CF, et al. The association between obesity and clinical features of psoriatic arthritis: a case-control study. J Rheumatol. 2017; 44: 437–443.
Maas F, Arends S, van der Veer E, et al. Obesity is common in axial spondyloarthritis and is associated with poor clinical outcome. J Rheumatol. 2016; 43: 383–387.
Lee YX, Kwan YH, Png WY, et al. Association of obesity with patient-reported outcomes in patients with axial spondyloarthritis: a cross-sectional study in an urban Asian population. Clin Rheumatol. 2017; 36: 2365–2370.
Sandberg ME, Bengtsson C, Källberg H, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. 2014; 73: 2029–2033.
Lupoli R, Pizzicato P, Scalera A, et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther. 2016; 18: 297.
Vidal C, Barnetche T, Morel J, et al. Association of body mass index categories with disease activity and radiographic joint damage in rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2015; 42: 2261–2269.
Tournadre A, Pereira B, Dutheil F, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle 2017; 8: 639–646.
Moisan A, Lee YK, Zhang JD, et al. White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol. 2015; 17: 57–67.
Højgaard P, Glintborg B, Kristensen LE, et al. The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford) 2016; 55: 2191–2199.
Iannone F, Fanizzi R, Scioscia C, et al. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy. Scand J Rheumatol. 2013; 42: 41–44.
Ottaviani S, Allanore Y, Tubach F, et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther. 2012; 14: R115.
Micheroli R, Hebeisen M, Wildi LM, et al. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther. 2017; 19: 164.